3 completed, 2 terminated, 1 active not recruiting, 1 unknown. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 3, Terminated 2, Active not recruiting 1, Unknown 1 |
| Phase 2 | 4 | Completed 2, Terminated 1, Unknown 1 |
Follow Digestive System Disease: new trials by email Literature Review of Digestive System Disease trials Research Report on Digestive System Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors IDRX-42 - Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST) | Phase 1 | Active not recruiting | IDRX, Inc., a wholly owned subsidiary of GSK, LLC | 276 | 2022-08-03 | 2026-10-05 |
| A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) THE-630 - Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue | Phase 1 / Phase 2 | Terminated | Theseus Pharmaceuticals | 32 | 2022-01-03 | 2024-06-05 |
| A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer Nab-paclitaxel, Gemcitabine, Capecitabine - Adenocarcinoma, Pancreatic Neoplasms | Phase 1 / Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 48 | 2018-06-21 | 2024-12-31 |
| A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease PvP001 placebo, PvP001 100 mg, PvP001 300 mg - Digestive System Disease | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 139 | 2018-06-19 | 2023-04-04 |
| Gastric Gluten-Degradation Activity of PvP001 Low-dose PvP001, Medium-dose PvP001, High-dose PvP001 - Digestive System Disease | Phase 1 | Terminated | Danielle Kim Turgeon | 43 | 2018-05-25 | 2019-02-15 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 590 | 2017-03-17 | 2025-05-31 |
| Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis conventional therapy plus MenSC transplantation, Conventional therapy plus placebo treatment - Liver Cirrhosis, Fibrosis | Phase 1 / Phase 2 | Unknown | S-Evans Biosciences Co., Ltd. | 50 | 2010-10-01 | 2012-06-07 |
Digestive System Diseases (7) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Neoplasms (3) · Adenocarcinoma (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Gastrointestinal Stromal Tumors (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma, Papillary (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1)
Neoplasms by Site (3) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Bronchial Diseases (1) · Carcinoma (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1) · Digestive System Neoplasms (1) · Genetic Diseases, Inborn (1) · Multiple Endocrine Neoplasia (1) · Neoplasms (1) · Neoplasms, Connective Tissue (1) · Neoplasms, Connective and Soft Tissue (1) · Neoplasms, Ductal, Lobular, and Medullary (1)
130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Capecitabine (1) · Cisplatin (1) · Gemcitabine (1) · IDRX-42 (1) · Interferons (1) · Irinotecan (1) · Maximum Tolerated Dose (1) · Ursodeoxycholic Acid (1) · pralsetinib (1)
Danielle Kim Turgeon (1) · Hoffmann-La Roche (1) · IDRX, Inc., a wholly owned subsidiary of GSK, LLC (1) · Millennium Pharmaceuticals, Inc. (1) · S-Evans Biosciences Co., Ltd. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Theseus Pharmaceuticals (1)
United States (6) · China (3) · Belgium (2) · France (2) · Germany (2) · Italy (2) · Netherlands (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Hong Kong (1) · Japan (1) · Singapore (1) · Taiwan (1)
Charlie Xiang, Professor (1) · Danielle Kim Turgeon, MD (1) · Dung Le, MD (1) · Stew Kroll (1)
PMID 33741317, PMID 34118197, PMID 34118198, PMID 35715405, PMID 35962206, PMID 37282666, PMID 37916501, PMID 37934000, PMID 38009200, PMID 40639400, PMID 41886723
2016 (1)